Dashboard
Manage Tickers

ABBV AbbVie Inc.

NYSE abbvie.com


$ 228.04 $ 0.97 (0.43 %)    

Thursday, 30-Oct-2025 12:41:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 630.47 $ -1.55 (-0.25 %)
DIA $ 478.02 $ 3.84 (0.81 %)
SPY $ 684.10 $ 0.26 (0.04 %)
TLT $ 90.68 $ 0.28 (0.31 %)
GLD $ 367.93 $ 2.80 (0.77 %)
$ 225.14
$ 227.28
$ 227.96 x 400
$ 228.11 x 153
$ 227.01 - $ 229.59
$ 158.28 - $ 243.06
5,469,686
na
397.72B
$ 0.44
$ 105.69
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-04-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-20-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-17-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 02-18-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-02-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 02-19-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-05-2019 06-30-2019 10-Q
26 05-03-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 02-16-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 02-17-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

abbvies-earnings-outlook
AbbVie's Earnings Outlook
10/30/2025 14:02:37

abbvie-says-canadas-drug-agency-recommends-elahere-be-reimbursed-with-conditions-for-treatment-of-certain-types-of-platinum-resistant-ovarian-cancers
AbbVie Says Canada's Drug Agency Recommend...
10/30/2025 11:31:44

ELAHERE® receives a positive recommendation by Canada's Drug Agency (CDA-AMC)ELAHERE® was submitted for reimbursement revie...

abbvie-says-in-two-replicate-phase-3-studies-rinvoq-achieved-co-primary-endpoints-of-50-reduction-in-total-vitiligo-area-scoring-index-from-baseline-and-75-in-facial-vitiligo-area-scoring-index
AbbVie Says In Two Replicate Phase 3 Studi...
10/29/2025 12:14:18

retail-investors-top-stocks-with-earnings-this-week-sofi-apple-meta-and-more
Retail Investors' Top Stocks With Earnings...
10/27/2025 14:38:22

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 

live-on-cnbc-rob-sechan-announces-bought-more-abbvie
Live On CNBC, Rob Sechan Announces Bought ...
10/24/2025 16:30:49

qualcomm-aptiv-palo-alto-and-a-health-care-stock-on-cnbcs-final-trades
Qualcomm, Aptiv, Palo Alto And A Health Ca...
10/22/2025 12:17:16

Jason Snipe stays long on AbbVie (ABBV). Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Steph...

Core News & Articles
CNBC Halftime Report Final Trades: Palo Al...
10/21/2025 17:01:52

guggenheim-maintains-buy-on-abbvie-raises-price-target-to-242
Guggenheim Maintains Buy on AbbVie, Raises...
10/20/2025 12:34:56

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $227 to $242.

abbvie-announced-topline-results-from-the-phase-3b4-head-to-head-select-switch-study-evaluating-the-efficacy-and-safety-of-upadacitinib-says-upadacitinib-outperforms-adalimumab-in-study-achieves-key-efficacy-endpoints-with-no-new-safety-risks
AbbVie Announced Topline Results From The ...
10/20/2025 12:10:56

Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) ...

raymond-james-reiterates-outperform-on-abbvie-raises-price-target-to-250
Raymond James Reiterates Outperform on Abb...
10/17/2025 16:07:17

Raymond James analyst Gary Nachman reiterates AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $236 to ...

amazon-abbvie-datadog-and-a-financial-stock-cnbcs-final-trades
Amazon, AbbVie, Datadog And A Financial St...
10/14/2025 12:17:04

Analysts discuss stock performance and potential of AbbVie Inc, Amazon, Sixth Street Specialty Lending, and Datadog. Check out ...

if-you-invested-100-in-abbvie-stock-10-years-ago-you-would-have-this-much-today
If You Invested $100 In AbbVie Stock 10 Ye...
10/13/2025 21:00:34

Core News & Articles
CNBC Halftime Report Final Trades: AbbVie,...
10/13/2025 17:01:06

abbvie-says-fda-approves-snda-that-updates-indication-statement-for-rinvoq-for-treatment-of-adults-with-uc-and-cd
AbbVie Says FDA Approves sNDA That Updates...
10/13/2025 15:00:29

-        Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking a...

abbvie-to-present-new-adc-data-at-esmo-congress-2025-highlighting-temab-a-abbv-706-and-emrelis-in-difficult-to-treat-tumors
AbbVie To Present New ADC Data At ESMO Con...
10/13/2025 11:18:16

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progre...

piper-sandler-maintains-overweight-on-abbvie-raises-price-target-to-284
Piper Sandler Maintains Overweight on AbbV...
10/10/2025 12:38:43

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $2...

Core News & Articles
A Congress Member Sold Up To $300K In A.O....
10/08/2025 15:00:28

abbvies-botox-shows-improvement-in-movement-disorder-study
AbbVie's Botox Shows Improvement In Moveme...
10/06/2025 14:54:17

AbbVie's Phase 2 ELATE trial shows onabotulinumtoxinA improves tremor scores and meets all endpoints, offering a new option...

abbvies-botox-meets-primary-and-all-secondary-endpoints-in-phase-2-elate-trial-for-upper-limb-essential-tremor
AbbVie's BOTOX Meets Primary And All Secon...
10/06/2025 13:06:06

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvemen...

abbvie-expects-q3-earnings-to-include-27b-iprd-expense-q3-adj-eps-guidance-range-is-174---178-sees-fy25-adj-eps-guidance-range-including-iprd-impact-is-1038---1058
AbbVie Expects Q3 Earnings To Include $2.7...
10/03/2025 20:14:48

Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION